The Frequency of Prevotella Species in Women with Bacterial Vaginosis and Detection of the Drug Resistance

Document Type : Original Article

Authors

Midwife, Nursing and Midwifery School, Hamadan University of Medical Sciences, Hamadan, Iran

Abstract

Introduction: Recently drug resistance to three species of Prevatella (P.bivia, P. melaninogemcus, P. disicns) is seen. The aim of this study was to evaluate the frequency of bacterial vaginosis and detection of drugs resistance of Prevotella species.
Materials and Methods: This descriptive study performed from 2004 to 2005 at Fatemi Hospital of Hamadan, Iran, on 310 female patients with vaginal discharge. This study was approved by the local committee of medical ethics. Laboratory diagnosis of bacterial vaginosis was based on 4 criteria including study of the homogenesity of the discharges, performing of whiff test, search for clue cell in smear and determination of pH of the discharge. Antibiogram test was performed by method of Kirby-Bauer and 9 commonly used antibiotics were applied. The data collected in a questionnaire and analyzed, using spss software.
 
Results: Of 310 patients with discharge, 65.7% were diagnosed as bacterial vaginosis that 47.4% of them had clue cells, 66.2% were whiff test positive, pH of 87.1% of the discharge were more than 4.5 and 76.7% had non-homogenous discharge. Out of 310 samples, 60 (19.3%) Prevotella species isolated in which 80% was P.bivia, 11.6%P.disiens and 8.3% P.melaninogenicus.These isolates and 4 references strains were resistant to penicillin (100%) and to vancomycin, kanamycin (> 60%). Resistance to cefoxcetin, clindamycin, metronidazole and ciprofloxacin were less than 10%.
 
Conclusion: The frequency of bacterial vaginosis in our patients was relatively high. The most frequent isolated strain was P.bivia and also the most effective antibiotics against Prevotella isolates were ciprofloxacin, cefoxcetin, clindamycin and metronidazole.

Keywords

References

1- Morton AN, Bradshaw CS, Fairley CK. Changes in the diagnosis and management of bacterial
vaginosis following clinical research.Sex Health 2006; 3(3):183-5.
2- Eschenbach DA. Pelvic infections and sexually transmitted diseases. In: Scott JS, Gibbs RS,
Karlan BY, Haney AF. Danforlh’s obstetrics & gynecology. 9th ed.Lippincott: William &
Wilkins; 2005. 581-604.
3- Holmes KK, Spiegel R, Amesel DA. Eschenbach DA, Chen KC, Totten P. Non specific
vaginosis.Scan.J.Infect.Dis 1981; 26 : 110-114.
4- Amsel R, Totten PA, Spiegel CA, Chen KC, Eschenbach D, Holmes KK. Nonspecific vaginitis:
diagnostic criteria and microbial and epidemiologic associations. Am J Med 1983; 74:14-22.
5- Mashburn J. J Midwifery Womens Health. Etiology, diagnosis, and management of vaginitis.
Womens Health 2006; 51(6):423-30.
6- McCormak WM. Vulvovaginitis and cervicitis. In: Mandell GL, Bennet J.E, Doli R editors.
Principles and practice at infections disease. 6th ed. New york: Churchill Livingstone; 2005.
1357-1371.
7- Rosene K,Eschenbach DA,Tompkins LS,Kenny GE, Watkins H. Polymicrobial early postpartum
ndometritis with facultative and anaerobic bacteria; genital mycoplasmas, and Chlamydia
trachomatis; Treatment whit piperacillin or cefoxitin. J Infect Dis 1986; 153: 1028-1037.
8- Lindner LE, Geerling S, Nettum JA, Miller SL, Altman KH. Clinical characterisitic of women
whit chlamydial cervicitis.J Repord Med 1988; 33(8): 684-90.
9- Shah HN, Collins MD. Proposal to restrict the genus Bacteroides (Castellani and Chalmens) to
Bacteroides fragilis and closely related species. Int J Syst Bacteriol 1989; 39: 85-91.
10- Yousefi Mashouf R, Duerden BI. An identification scheme for oral non-pigmented Prevotella
(Bacteroides) species. Microbial Ecol Health Dis 1992; 5(1): 31-34.
11- Teanpaisan R, Douglas CW, Eley AR, Walsh TF.Clonality of Porphyromonas gingivalis,
Prevotella intermedia and Prevotella nigrescens isolated from periodontally diseased and healthy
sites. J Periodontal Res 1996; 31(6):423-32.
12- Strömbeck L, Sandros J, Holst E, Madianos P, Nannmark U, Papapanou P, et al. Prevotella bivia
can invade human cervix epithelial (HeLa) cells. APMIS 2007;115(3):241-51.
13- Mikamo H, Kawazoe K, Sato Y, Imai A, Tamaya T. Preterm labor and bacterial intra-amniotic
infection: arachidonic acid liberation by phospholipase A2 of Prevotella bivia. Anaerobe 1998;
4(5):209-12
14- Austin MN, Beigi RH, Meyn LA, Hillier SL. Microbiological response to treatment of bacterial
vaginosis with topical clindamycin or metronidazole. J Clin Microbiol 2005; 43(9):4492-7.
15- Behra-Miellet J, Calvet L, Mory F, Muller C, Chomarat M, Bézian MC, et al. Antibiotic
resistance among anaerobic gram negative bacilli: lessons from a French multicentric survey.
Anaerobe 2003; 9:105-111.
16- Beigi, RH, Austin MN, Meyn LA, Krohn MA and Hillier SL. Antimicrobial resistance
associated with the treatment of bacterial vaginosis. Am J Obstet Gynecol 2004; 191:1124-29.
17- Boris, J, Pahlson C, Larsson PG. Six years of observation after successful treatment of bacterial
vaginosis. Infect Dis Obstet Gynecol. 1997; 5:297-302.
18- Bahar H, Torun MM, Demirci M, Kocazeybek B. Antimicrobial resistance and beta-lactamase
production of clinical isolates of prevotella and porphyromonas species. Chemotherapy 2005;
51(1):9-14.
19- Yasin B, Pang M, Lehrer RI, Wagar EA.. Activity of Novispirin G-10, a novel antimicrobial
peptide against Chlamydia trachomatis and vaginosis-associated bacteria. Exp Mol Pathol 2003;
74(2):190-5.
20- Baron EJ, Peterson LR, Finegold SM. Bailey and scott
,
s Diagnostic Microbiology. 9th ed.
Mosby, U.S.A. 1994. 258-71.
21- Bauer AW, Kirby WM ,Sheriss JC. Antibiotic susceptibility testing by a standardized single
disck method. AM J Clin Patho 1996; 45: 493-96.
22- Fleury FJ. Adult vaginitis. Clin Obset.Gynecol.1981; 24: 407-412.
23- Holmes KK. Sexually transmitted diseases. In: Fauci AS, Braunwald E, Eugene B, Isselbacher
KJ. Harrison`s principles of internal medicine. 16th ed. New York: Mc Graw – Hill; 2005. P.
762-74. 
 
24- Vogel I, Thorsen P, Jeune B, Jacobsson B, Ebbesen N, Arpi M, et al. Acquisition and
elimination of bacterial vaginosis during pregnancy: a danish population-based study. Infect Dis
Obstet Gynecol 2006 ;14(3):946.
25- Jones FR, Miller G, Gadea N, Meza R, Leon S, Perez J, et al. Prevalence of bacterial vaginosis
among young women in low-income populations of coastal Peru. Int J STD AIDS 2007;
18(3):188-92
26- Escenbach DA, Sharon Hilier S, Critchlow C, Penk W. Diagnosis of anaerobic and clinical
manifestations of bacterial vaginosis. Am J Obstet Gynecol 1988; 158: 819-28.
27- Leta Qching, Knneth A, Sorchardt A. 24 hour plastic envelop method for isolation and
identifying Garnerella vaginalis (Pe.Ga). Genitourin Med 1988; 64: 180-84.
28- Pandit DV, Barve SM, Deodhar LP. Biotypes of gardnerella vaginalis isolated from non specific
vaginitis patients in Bombay. Indian J Med Res 1989; 435-38.
29- Demba E, Morison L, Schim van der Loeff M, Awasana A.A, Gooding E, Bailey R, et al.
Bacterial vaginosis, vaginal flora patterns and vaginal hygiene practices in patients presenting
with vaginal discharge syndrome in The Gambia, West Africa. BMC Infect Dis 2005; 5: 12.
30- Taghriri A, Danesh A. Bacterial vaginosis in patients referring to medical centers in Sharekord,
2004-2005. Feyz Winter 2006; 4 (9): 31-34. (Original in Persian)
31- Borjian S, Shojaei H, Shahaniyan M, Deris F. Diagnisis of gardenella associated vaginosis in
Borujen women's outpatients clinic, 2000. Sharekord Un Med ScieJ Winter 2002; 3(4): 38-44.
(Original in Persian)
32- Afrakhteh M, Atossa M. Bacterial vaginosis and urinary tract infection. I J Obstett, Gynecol
Infertil Summer 2006; 9(1): 108-113. (Original in Persian)
33- Centers for Disease Control. Sexually transmitted diseases treatment guidelines. Morb. Mortal
Wkly Rep 2002; 51:42-48.
34- Ednie LM, Credito KL, Khantipong M, Jacobs MR, Appelbaum PC. Synergic activity, for
anaerobes, of trovafloxacin with clindamycin or metronidazole: chequerboard and time-kill
methods. J Antimicrob Chemother 2000; 45(5):633-8.
35- Suzuki Y, Nishinari C, Endo H, Tamura C, Jinbo K, Hiramatsu N, et al. Yearly changes in
antibacterial activities of cefozopran against various clinical isolates between 1996 and 2000--II.
Gram-negative bacteria. Jpn J Antibiot 2002; 55(2):154-80.
36- Mikamo H, Yin XH, Ninomiya M, Tamaya T. In vitro and in vivo antibacterial activities of
telithromycin. Chemotherapy 2003; 49(1-2):62-5.
37- Mikamo H, Sato Y, Hayasaki Y, Kawazoe K, Tamaya T. In vitro activities of pazufloxacin, a
novel injectable quinolone, against bacteria causing infections in obstetric and gynecological
patients. Chemotherapy 1999; 45(3):154-7. 

Files

Share

How to cite

Statistics